Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Hyun Yong Jin, Franck Morschhauser, Luca Laurenti et al.|Blood|2025

Cited by 0